Tendersinfo Gulf

Filter Search

Healthcare and Medical

Location Summary Deadline
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Teduglutide, Atc A16ax08 For The Period June 1st, 2026 - May 31st, 2028 (plus Extension Option 1x12 Months) 2029-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Piperacillin + Tazobactam, Atc J01cr05 For The Period June 1st, 2026 - May 31st, 2028 (plus V. Option 1x12 Months) 2029-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Tianeptine, Atc N06ax14 For The Period June 1st, 2026 - May 31st, 2028 (plus Extension Option 1x12 Months) 2029-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V For The Active Ingredient Teduglutide, Atc A16ax08 For The Period 01.06.2026 To 31.05.2028 (plus Extension Option 1x12 Months) 2029-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V For The Active Ingredient Clobazam (excluding Dafo Tab), Atc N05ba09 For The Period 01.06.2026 To 31.05.2028 (plus Option For 1x12 Months) 2029-04-05
Germany The Dak-gesundheit Intends To Conclude A Non-exclusive Discount Agreement Under § 130a Abs. 8 Sgb V For The Active Ingredient Mesalazine (excluding Dafo Rsu + Kli), Atc A07ec02 For The Period From 01.06.2026 To 31.05.2028, With An Option To Extend For 1x1 2029-04-05
Germany The Dak-gesundheit Intends To Conclude A Non-exclusive Discount Agreement For The Active Ingredient Prednicarbat, Atc D07ac18, For The Period From June 1, 2026, To May 31, 2028, With An Option For A 12-month Extension. This Agreement Is Based On § 130a Ab 2029-04-05
Germany The Dak-gesundheit Intends To Conclude A Non-exclusive Discount Agreement For The Active Ingredient Bexaroten, Atc L01xf03, For The Period From June 1, 2026, To May 31, 2028, With An Option For A 12-month Extension. This Agreement Is Based On § 130a Abs. 2029-04-05
Germany The Dak-gesundheit Intends To Conclude A Non-exclusive Discount Agreement For The Active Ingredient Pomalidomide, Atc L04ax06, For The Period From June 1, 2026, To May 31, 2028, With An Option For A 12-month Extension. This Agreement Is Based On § 130a Ab 2029-04-05
Germany The Dak-gesundheit Intends To Conclude A Non-exclusive Discount Agreement Under § 130a Abs. 8 Sgb V For The Active Ingredient Clobazam (excluding Dafo Sue), Atc N05ba09 For The Period From 01.06.2026 To 31.05.2028 (plus An Extension Option Of 1x12 Months) 2029-04-05
Whats app